Mannkind Corp (MNKD) Stock Price, Quote & News

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pul...

Industry: Biotechnology

Sector: Healthcare

Phone: 818 661 5000

Website: www.mannkindcorp.com

Address:

1 Casper Street, Danbury, United States

pierrules Aug. 25 at 10:18 AM

$MNKD 😎🌞😎🌞

0 · Reply

clan Aug. 24 at 9:48 PM

$MNKD Buzz, it's going to start looking/feeling/sounding a lot more positive around here in a few months.🚀

0 · Reply

eve_t_s_oloccip Aug. 24 at 7:03 PM

$MNKD The #Facts

0 · Reply

Winning_calls Aug. 24 at 4:58 PM

$MNKD pick me up @ $4.13

0 · Reply

Igotzthis Aug. 24 at 4:21 PM

$MNKD I was wondering. If UTHR gets an indication for IPF does the same agreement still hold for manufacturing and royalties or can we renegotiate the terms?

1 · Reply

masspd Aug. 24 at 1:15 PM

$MNKD to the science folks- I have a quick question. Does United have any recon on the Teton 2 trial results now? Dropouts or something like that which helps predict the outcome.

2 · Reply

masspd Aug. 24 at 12:14 PM

$MNKD so is it safe to assume IF Teton 2 has solid results that UTHR will see anticipated stock appreciation? I then assume MNKD will see the same love from being guilty by association? DPI bridge study equals more $$$ for MNKD! These analysts don’t have good news baked into the stock price yet, giddy up, Sept is almost upon us!

0 · Reply

Igotzthis Aug. 24 at 3:56 AM

$MNKD I can’t believe how many of you missed the boat on Pulmatrix. Everything was right in front of you. Now most of you will miss the boat on MNKD. Or will you???

4 · Reply

kevinmik Aug. 24 at 12:43 AM

$MNKD I expect when Pulmatrix announces their merger with Cullgen is completed, an announcement will come out that Mannkind has purchased Pulmatrix divested assets. The purchase price to acquire Pulmatric divested assets could cost Mannkind around $20 - $25 million. The deal will expand and diversify Mannkind adding significant value. JMO

1 · Reply

clan Aug. 23 at 9:54 PM

$MNKD To see the past, look at a rear view mirror. If you want to see today, look out the window. If you want to see the future, look at the images below.

0 · Reply

MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript

Aug 6, 2025, 4:44 PM EDT - 18 days ago

MannKind Corporation: A Post-Q2 Assessment

Aug 6, 2025, 7:10 AM EDT - 18 days ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Aug 6, 2025, 7:05 AM EDT - 18 days ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Jul 30, 2025, 4:05 PM EDT - 25 days ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Jun 11, 2025, 7:01 AM EDT - 2 months ago

Top 3 Health Care Stocks That May Rocket Higher This Quarter

Jun 9, 2025, 4:05 PM EDT - 2 months ago

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

May 27, 2025, 9:15 AM EDT - 3 months ago

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025, 12:02 AM EDT - 3 months ago

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition

May 13, 2025, 4:05 PM EDT - 3 months ago

MannKind to Present at Upcoming Investor Conferences

May 8, 2025, 11:34 AM EDT - 3 months ago

MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:05 AM EDT - 3 months ago

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:05 PM EDT - 4 months ago

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

Apr 7, 2025, 12:30 PM EDT - 4 months ago

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

Mar 10, 2025, 6:05 AM EDT - 6 months ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Feb 27, 2025, 10:32 AM EST - 6 months ago

MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question

Feb 26, 2025, 9:09 PM EST - 6 months ago

MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 6 months ago

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 4:05 PM EST - 6 months ago

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Feb 3, 2025, 9:20 AM EST - 7 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MSTR SKE SKYE AMSC

Jan 6, 2025, 4:30 PM EST - 8 months ago

MannKind Expands Executive Leadership Team

Dec 17, 2024, 7:16 AM EST - 8 months ago

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Dec 16, 2024, 6:05 AM EST - 8 months ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Dec 11, 2024, 6:00 AM EST - 9 months ago

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

Nov 7, 2024, 8:30 PM EST - 10 months ago

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 4:02 PM EST - 10 months ago

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Nov 5, 2024, 4:15 PM EST - 10 months ago

MannKind to Present at 2024 UBS Healthcare Conference

Nov 4, 2024, 6:05 AM EST - 10 months ago

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

Oct 31, 2024, 4:05 PM EDT - 10 months ago

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

Oct 30, 2024, 9:00 PM EDT - 10 months ago

First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Oct 3, 2024, 8:00 AM EDT - 11 months ago

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Sep 30, 2024, 6:00 AM EDT - 11 months ago

More Adults With Type 1 Diabetes Achieved A1C Goal (

Sep 18, 2024, 6:15 AM EDT - 1 year ago

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Sep 10, 2024, 4:30 PM EDT - 1 year ago

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 27, 2024, 4:30 PM EDT - 1 year ago

MannKind to Present at Upcoming Conferences

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board

Aug 7, 2024, 12:29 PM EDT - 1 year ago

MannKind Corporation (MNKD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 8:00 AM EDT - 1 year ago

MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

Jul 31, 2024, 6:30 AM EDT - 1 year ago

MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease

Jul 30, 2024, 4:30 PM EDT - 1 year ago

MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024

Jun 22, 2024, 8:00 AM EDT - 1 year ago

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions

Jun 5, 2024, 6:45 AM EDT - 1 year ago

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions

May 29, 2024, 8:45 AM EDT - 1 year ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

PULM

May 29, 2024, 8:45 AM EDT - 1 year ago

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix

May 8, 2024, 8:55 PM EDT - 1 year ago

MannKind Corporation (MNKD) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:18 PM EDT - 1 year ago

MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update

May 6, 2024, 6:05 AM EDT - 1 year ago

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

May 1, 2024, 4:00 PM EDT - 1 year ago

MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024

Apr 30, 2024, 6:05 AM EDT - 1 year ago

MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases

Apr 29, 2024, 6:05 AM EDT - 1 year ago

MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung Disease

pierrules Aug. 25 at 10:18 AM

$MNKD 😎🌞😎🌞

0 · Reply

clan Aug. 24 at 9:48 PM

$MNKD Buzz, it's going to start looking/feeling/sounding a lot more positive around here in a few months.🚀

0 · Reply

eve_t_s_oloccip Aug. 24 at 7:03 PM

$MNKD The #Facts

0 · Reply

Winning_calls Aug. 24 at 4:58 PM

$MNKD pick me up @ $4.13

0 · Reply

Igotzthis Aug. 24 at 4:21 PM

$MNKD I was wondering. If UTHR gets an indication for IPF does the same agreement still hold for manufacturing and royalties or can we renegotiate the terms?

1 · Reply

masspd Aug. 24 at 1:15 PM

$MNKD to the science folks- I have a quick question. Does United have any recon on the Teton 2 trial results now? Dropouts or something like that which helps predict the outcome.

2 · Reply

masspd Aug. 24 at 12:14 PM

0 · Reply

Igotzthis Aug. 24 at 3:56 AM

$MNKD I can’t believe how many of you missed the boat on Pulmatrix. Everything was right in front of you. Now most of you will miss the boat on MNKD. Or will you???

4 · Reply

kevinmik Aug. 24 at 12:43 AM

1 · Reply

clan Aug. 23 at 9:54 PM

$MNKD To see the past, look at a rear view mirror. If you want to see today, look out the window. If you want to see the future, look at the images below.

0 · Reply

kevinmik Aug. 23 at 7:33 PM

$MNKD MNKD raised capital from Blackstone that could be used to acqure Pulatrix divested assets. A good bolt-on aquisition Bolt-On Acquistion: A strategy to grow portfolio and increase value. Advantages include efficiency & effectiveness in scaling operations, entering new markets, or adding product offerings without the investment required to build these capabilities from scratch Pulmatrix Divested Assest ISPERSE™ Technology - MNKD licensed DPI technology & acquired Pulmatrix research laboratory in Boston. Pulmatrix transferred the facility & all laboratory equipment to MNKD PUR3100 - Orally inhaled iSPERSE DPI technology for the treatment of acute migraine. Ready for Phase II PUR1800 - Narrow Spectrum Kinase Inhibitor, iSPERSE™ technology, to treat chronic obstructive pulmonary disease PUR1900 - Inhaled iSPERSE formulation of the antifungal drug itraconazole. Partnered with Cipla ex-U.S. approved in to proceed with a Phase 3 clinical trial. CIPLA pays 2% royalty ex-U.S.

2 · Reply

NatesNotes Aug. 23 at 5:23 PM

It looks like it is shaping up to be another busy weekend for The False Narrative Crew here on the $MNKD stream, eh? What could their motive possibly be in trying to convince everyone else how bad things are (and apparently have been for the past 5+ years, no less!) while they, themselves, have continued to hold/buy the stock along the way?? ;-) #InTheirOwnWords #MikehastwoGo #noSECnoproblem #knowwhatyouown #factsmatter

0 · Reply

RockitMann Aug. 23 at 4:44 PM

$MNKD This company's mission statement is "to enrich management and the board wealth while slow rolling the development and release of novel medical treatments."

1 · Reply

masspd Aug. 23 at 1:40 PM

$MNKD why is Teton 2 in question? Nothing is done until it’s done but thought this had a high probability. Is this just scare tactics? The analyst acknowledged that while doubts regarding the upcoming TETON-2 study results for Tyvaso in IPF persist, the company’s current valuation remains attractive.

3 · Reply

Yasherp Aug. 23 at 4:48 AM

$MNKD Leerink Partners Reiterates a Buy on MannKind Corporation (MNKD), Keeps the PT - Talha Qureshi Sat, August 23, 2025 at 11:45 AM MannKind Corporation (NASDAQ:MNKD) is one of the Most Oversold Penny Stocks to Buy Now. On August 6, Faisal Khurshid from Leerink Partners reiterated a Buy rating on MannKind Corporation (NASDAQ:MNKD) with a price target of $7. https://finance.yahoo.com/news/leerink-partners-reiterates-buy-mannkind-034530254.html

0 · Reply

addiction2money Aug. 23 at 3:11 AM

$MNKD at least Mannkind SH’s would stand a chance if MC resigned. It’s been far overdue for his departure. Tired of this mediocre performance BS.

3 · Reply

clan Aug. 22 at 10:25 PM

$MNKD For all the Lasagna-haters trolling this board ... One day, this could be a division of $AMGN $MRK or $NVS

1 · Reply

clan Aug. 22 at 10:11 PM

$MNKD A new drug will be added/announced to the pipeline before the end of this year. Just an FYI.

1 · Reply

clan Aug. 22 at 9:37 PM

$MNKD Someone tell the ogre living in a grass hut in Cambodia, who "entertains" street hookers in his boom-boom room, that there's another open gap to be filled for MNKD. #BreakOut #Reversal

0 · Reply

TwitsNelson123 Aug. 22 at 8:57 PM

$MNKD

0 · Reply

clan Aug. 22 at 8:56 PM

$MNKD Don't forget about Cipla. $CIPLA.NSE 🇮🇳

0 · Reply

Michaelluh Aug. 22 at 8:54 PM

$MNKD Will dig down into each one next week before events and speculate playbook for each.

1 · Reply

Market Cap	1.26B
Revenue (ttm)	285.50M
Net Income (ttm)	27.59M
EPS (ttm)	N/A
PE Ratio	35.82
Forward PE	45.03
Profit Margin	9.66%
Debt to Equity Ratio	-2.54

Volume	3,052,000
Avg Vol	3,109,152
Day's Range	N/A - N/A
Shares Out	306.83M
Stochastic %K	99%
Beta	1.02
Analysts	Strong Sell
Price Target	$9.25